Immunome, Inc. (IMNM) Wins FDA IND Clearance for IM-1340 ADC

Immunome received FDA clearance of its IND for IM-1340, a potential first-in-class ADC for advanced solid tumors, and expects to start a Phase 1 dose-escalation/expansion trial in Q4 2026.Material DetailsContext by AI AnalystThis is an early-stage pipeline step, adding another ADC to Immunome’s cli…